NAMSA has completed the acquisition of select assets from Labcorp’s Early Development medical device testing business. The deal includes the U.S. portfolio of services such as biocompatibility, microbiological, analytical testing, and preclinical research.
The acquisition aims to expand NAMSA’s offerings in medical device development and provide clients with broader expertise throughout the product lifecycle. NAMSA will now conduct future testing and preclinical projects for Labcorp’s former clients at its facilities in Ohio, Minnesota, Georgia, and California.
Brian Smith, CEO of NAMSA, stated: "This acquisition is a perfect fit for NAMSA - we serve 3,000+ MedTech companies globally in these specific areas of testing and preclinical research. I am confident we will be able to provide Labcorp's medical device clients with a smooth transition combined with the same high level of expertise and customer service current NAMSA clients have come to expect from us."
Labcorp will focus on its core areas following this transaction. Brian Caveney, M.D., EVP and President of Early Development Research Laboratories at Labcorp said: "The sale of our Early Development medical device testing business to NAMSA allows Labcorp to focus on core areas of preclinical drug development and chemical testing. We are pleased NAMSA will continue providing leading expertise to clients in this space and are committed to a seamless transition."
NAMSA operates globally with locations across the United States, Europe, and Asia. The company was acquired by ARCHIMED in 2020; this marks its tenth acquisition since then.
